- Home
- EDIT vs VERU Comparison
EDIT vs VERU Comparison
Compare EDIT & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- VERU
- Stock Information
- Founded
- EDIT 2013
- VERU 1971
- Country
- EDIT United States
- VERU United States
- Employees
- EDIT N/A
- VERU N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- EDIT Health Care
- VERU Health Care
- Exchange
- EDIT Nasdaq
- VERU Nasdaq
- Market Cap
- EDIT 108.1M
- VERU 108.8M
- IPO Year
- EDIT 2016
- VERU 1990
- Fundamental
- Price
- EDIT $1.92
- VERU $0.57
- Analyst Decision
- EDIT Buy
- VERU Strong Buy
- Analyst Count
- EDIT 14
- VERU 4
- Target Price
- EDIT $8.08
- VERU $4.00
- AVG Volume (30 Days)
- EDIT 5.8M
- VERU 6.2M
- Earning Date
- EDIT 03-03-2025
- VERU 02-13-2025
- Dividend Yield
- EDIT N/A
- VERU N/A
- EPS Growth
- EDIT N/A
- VERU N/A
- EPS
- EDIT N/A
- VERU N/A
- Revenue
- EDIT $61,759,000.00
- VERU $16,886,419.00
- Revenue This Year
- EDIT N/A
- VERU N/A
- Revenue Next Year
- EDIT N/A
- VERU N/A
- P/E Ratio
- EDIT N/A
- VERU N/A
- Revenue Growth
- EDIT 150.95
- VERU 22.46
- 52 Week Low
- EDIT $1.12
- VERU $0.49
- 52 Week High
- EDIT $11.58
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- EDIT 55.72
- VERU 44.48
- Support Level
- EDIT $1.12
- VERU $0.49
- Resistance Level
- EDIT $3.30
- VERU $0.56
- Average True Range (ATR)
- EDIT 0.30
- VERU 0.05
- MACD
- EDIT 0.12
- VERU 0.00
- Stochastic Oscillator
- EDIT 36.70
- VERU 63.62
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.